Beaumont Financial Partners LLC Has $288,000 Holdings in SPDR S&P Biotech ETF (XBI)

Beaumont Financial Partners LLC reduced its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 91.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,003 shares of the exchange traded fund’s stock after selling 33,022 shares during the quarter. Beaumont Financial Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $288,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Morgan Stanley lifted its stake in shares of SPDR S&P Biotech ETF by 23.8% in the 2nd quarter. Morgan Stanley now owns 9,568,839 shares of the exchange traded fund’s stock valued at $910,858,000 after purchasing an additional 1,840,100 shares during the last quarter. Assetmark Inc. lifted its stake in shares of SPDR S&P Biotech ETF by 271,147.4% in the 2nd quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock valued at $120,321,000 after purchasing an additional 1,263,547 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of SPDR S&P Biotech ETF by 159.3% in the 2nd quarter. SG Americas Securities LLC now owns 977,702 shares of the exchange traded fund’s stock valued at $93,067,000 after purchasing an additional 600,603 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of SPDR S&P Biotech ETF by 9,533.7% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 209,437 shares of the exchange traded fund’s stock valued at $20,079,000 after purchasing an additional 207,263 shares during the last quarter. Finally, Howard Capital Management lifted its stake in shares of SPDR S&P Biotech ETF by 557.2% in the 2nd quarter. Howard Capital Management now owns 151,047 shares of the exchange traded fund’s stock valued at $14,378,000 after purchasing an additional 128,065 shares during the last quarter.

Shares of SPDR S&P Biotech ETF stock opened at $83.24 on Wednesday. SPDR S&P Biotech ETF has a 52 week low of $76.37 and a 52 week high of $101.55.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theenterpriseleader.com/2018/11/07/beaumont-financial-partners-llc-has-288000-holdings-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply